尼索地平对雷诺现象患者全血血小板聚集的影响。
The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.
作者信息
Francis J L, Roath O S, Challenor V F, Waller D G
机构信息
University Department of Haematology, Southampton General Hospital.
出版信息
Br J Clin Pharmacol. 1988 Jun;25(6):751-4. doi: 10.1111/j.1365-2125.1988.tb05262.x.
Abstract
- Whole blood platelet aggregation was measured by electrical impedance in 28 controls and 28 patients with primary Raynaud's phenomenon. 2. The patients were entered into a double-blind, placebo-controlled cross-over trial of the calcium antagonist nisoldipine, in which they received, in random order, three, 4 week treatments with placebo and nisoldipine (5 and 10 mg day-1). 3. Platelet aggregation responses to two concentrations (5.0 and 0.5 micrograms ml-1) of collagen were determined before treatment and at the end of each treatment phase. 4. There were no differences in aggregation response to either collagen concentration between controls and patients with primary Raynaud's phenomenon, or between placebo and active treatment phases. 5. These data do not support the suggestion that nisoldipine has a significant anti-platelet effect.
摘要
- 采用电阻抗法测量了28例对照者和28例原发性雷诺现象患者的全血血小板聚集情况。2. 患者进入一项双盲、安慰剂对照的钙拮抗剂尼索地平交叉试验，试验中他们随机接受为期4周的安慰剂和尼索地平（5毫克和10毫克/天）三种治疗。3. 在治疗前和每个治疗阶段结束时，测定血小板对两种浓度（5.0和0.5微克/毫升）胶原的聚集反应。4. 对照者与原发性雷诺现象患者之间，或安慰剂与活性治疗阶段之间，对两种胶原浓度的聚集反应均无差异。5. 这些数据不支持尼索地平具有显著抗血小板作用这一观点。
相似文献
1
The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.尼索地平对雷诺现象患者全血血小板聚集的影响。
Br J Clin Pharmacol. 1988 Jun;25(6):751-4. doi: 10.1111/j.1365-2125.1988.tb05262.x.
2
Nisoldipine in primary Raynaud's phenomenon.尼索地平治疗原发性雷诺现象。
Eur J Clin Pharmacol. 1987;33(1):27-30. doi: 10.1007/BF00610375.
3
Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.硝苯地平治疗特发性雷诺现象的对照双盲试验。
Eur J Clin Pharmacol. 1986;31(4):387-9. doi: 10.1007/BF00613511.
4
5
Abnormal platelet aggregation in patients with Raynaud's phenomenon.雷诺现象患者的血小板异常聚集。
J Clin Pathol. 1989 Jul;42(7):716-8. doi: 10.1136/jcp.42.7.716.
6
Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.维拉帕米和尼索地平对人血小板的作用：体内和体外研究
Br J Clin Pharmacol. 1985 Sep;20(3):191-6. doi: 10.1111/j.1365-2125.1985.tb05060.x.
7
Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.维拉帕米和尼索地平对人血小板的作用：体内和体外研究
Br J Clin Pharmacol. 1986 Aug;22(2):201-2. doi: 10.1111/j.1365-2125.1986.tb05252.x.
8
9
Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation.
Am J Med. 1985 Apr;78(4):602-8. doi: 10.1016/0002-9343(85)90402-4.
10
Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.达唑氧苯与硝苯地平治疗雷诺现象的对照双盲试验。
Am J Med. 1984 Sep;77(3):451-6. doi: 10.1016/0002-9343(84)90101-3.
引用本文的文献
1
Calcium channel blockers for primary Raynaud's phenomenon.用于原发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. doi: 10.1002/14651858.CD002069.pub5.
2
Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.尼索地平包衣片芯。其药理学及高血压治疗疗效综述。
Drugs. 1996 Aug;52(2):232-53. doi: 10.2165/00003495-199652020-00009.
3
Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.尼索地平。对其药效学、药代动力学特性以及治疗心绞痛、高血压和相关心血管疾病的疗效的初步综述。
Drugs. 1988 Dec;36(6):682-731. doi: 10.2165/00003495-198836060-00003.
本文引用的文献
1
Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide.抗心律失常药物维拉帕米和丙吡胺对血小板功能的抑制作用。
Thromb Haemost. 1982 Apr 30;47(2):150-3.
2
The effects of nifedipine, a calcium antagonist, on platelet function.钙拮抗剂硝苯地平对血小板功能的影响。
Am Heart J. 1983 Jan;105(1):103-5. doi: 10.1016/0002-8703(83)90285-5.
3
Effects of nifedipine (Adalat) on platelet function in vitro and in vivo.硝苯地平（心痛定）对体内外血小板功能的影响。
Thromb Res. 1981;21(4-5):523-8. doi: 10.1016/0049-3848(81)90155-9.
4
Inhibition of human platelet functions by verapamil.维拉帕米对人血小板功能的抑制作用。
Thromb Haemost. 1981 Apr 30;45(2):158-61.
5
Difficulty in detecting inhibition of platelet aggregation by the impedance method.通过阻抗法检测血小板聚集抑制的困难。
Thromb Res. 1982 Nov 1;28(3):427-32. doi: 10.1016/0049-3848(82)90124-4.
6
Plasma exchange and platelet function in Raynaud's phenomenon.
Thromb Res. 1980;19(1-2):85-93. doi: 10.1016/0049-3848(80)90406-5.
7
Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.钙通道阻滞剂硝苯地平对雷诺现象的影响。一项对照双盲试验。
J Rheumatol. 1984 Jun;11(3):362-4.
8
Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil.钙通道阻滞剂硝苯地平对人血小板活化的影响及其与维拉帕米的比较。
Thromb Haemost. 1983 Aug 30;50(2):513-7.
9
Assessment of platelet function in patients with Raynaud's syndrome.雷诺综合征患者血小板功能的评估。
J Clin Pathol. 1984 Feb;37(2):182-7. doi: 10.1136/jcp.37.2.182.
10
Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs.全血中的血小板阻抗聚集及其受抗血小板药物的抑制作用。
J Clin Pathol. 1984 Aug;37(8):874-8. doi: 10.1136/jcp.37.8.874.
Zotero 插件